Abstract

Study (n=141) reports improved median overall survival with addition of temozolomide to lomustine (31·4 months with temozolomide vs. 48·1 months with lomustine-temozolomide; HR 0·60, 95% CI 0·35–1·03; p=0·0492). Authors however highlight the small size of the trial.